debt investment, FVOCI - equity investment or FVTPL. Financial assets are not reclassified subsequent to their initial recognition unless the Company changes its business model for. | March 29, 2023
Chronic cough has a global prevalence of 5–10% in the general adult population (≥18
years);1 however, few effective treatment options are available for patients. Irrespective
of cause, many adult patients with chronic cough present with cough hypersensitivity,
which is a syndrome of troublesome coughing triggered by low levels of thermal, mechanical,
or chemical exposure. Recent scientific and clinical advances encompassing the burden
of chronic cough, underlying pathophysiological mechanisms, approaches to measuring
cough and cough hypersensitivity, current management approaches, and the development
of novel antitussive strategies (panel) were presented at the Twelfth London International
Cough Symposium (12th LICS) held at Imperial College London (London, UK) from July
13 to 14, 2022.
- Completed positive End-of-Phase 2 meeting with the Food and Drug Administration (“FDA”) and received scientific advice from the European Medicines Agency (“EMA”) to support design of its CALM Phase 3 program, which is expected to initiate in Q4 2022 Ended second quarter 2022 with approximately US$384.6 million.
BELLUS Health Reports Second Quarter 2022 Financial Results and Business Highlights streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
BELLUS Health Reports Second Quarter 2022 Financial Results and Business Highlights wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.